Can-Fite BioPharma (CANF) Investor Update summary

Financial and operational status

• Raised $5 million recently, with $4.7 million from the last financial period, providing funding for 16-18 months.

• Additional milestone payments from partners expected to further support operations.

• Over $20 million received from out-licensing deals, with $130 million in potential milestone payments ahead.

• Ongoing discussions with potential partners for further non-dilutive funding.

• No impact from regional conflicts as operations and manufacturing are outside Israel.

Clinical pipeline and development progress

• Lead drug Piclidenoson in pivotal phase III for psoriasis, with prior phase II/III studies showing efficacy and safety.

• Namodenoson in phase III for advanced liver cancer and phase IIa for pancreatic cancer, with interim analysis for liver cancer expected in the second half of next year.

• Phase IIb study ongoing for MASH (formerly NASH), with positive data expected to enable phase III.

• CF602 for erectile dysfunction remains in preclinical development.

Licensing and partnerships

• Multiple out-licensing agreements in Europe, China, Korea, Canada, and with Vetbiolix for veterinary use.

• Vetbiolix partnership for pet osteoarthritis drug recently showed strong clinical results in Beagles.

• Anticipated revenue from Vetbiolix and potential new partnership deals in the near term.